PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

SUBMISSION TYPE: NEW ASSIGNMENT

NATURE OF CONVEYANCE: ASSIGNMENT

CONVEYING PARTY DATA

<table>
<thead>
<tr>
<th>Name</th>
<th>Execution Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANGIODYNAMICS, INC.</td>
<td>11/09/2017</td>
</tr>
<tr>
<td>CLINICAL DEVICES B.V.</td>
<td>11/09/2017</td>
</tr>
</tbody>
</table>

RECEIVING PARTY DATA

<table>
<thead>
<tr>
<th>Name</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>BEL HOLDING B.V.</td>
<td></td>
</tr>
<tr>
<td>HEIKAMPSTRAAT 2, 5342 ND</td>
<td></td>
</tr>
<tr>
<td>OSS</td>
<td></td>
</tr>
<tr>
<td>NETHERLANDS</td>
<td></td>
</tr>
<tr>
<td>VELDHOEVE HOLDING B.V.</td>
<td></td>
</tr>
<tr>
<td>SNOERTSEBAAN 24, 5757 PB</td>
<td></td>
</tr>
<tr>
<td>LIESSEL</td>
<td></td>
</tr>
<tr>
<td>NETHERLANDS</td>
<td></td>
</tr>
</tbody>
</table>

PROPERTY NUMBERS Total: 5

<table>
<thead>
<tr>
<th>Property Type</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Number</td>
<td>14022379</td>
</tr>
<tr>
<td>Patent Number</td>
<td>9445746</td>
</tr>
<tr>
<td>Patent Number</td>
<td>9440047</td>
</tr>
<tr>
<td>Application Number</td>
<td>15232251</td>
</tr>
<tr>
<td>Patent Number</td>
<td>9877665</td>
</tr>
</tbody>
</table>

CORRESPONDENCE DATA

Fax Number: (412)471-4094

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 412 471 8815
Email: assignments@webblaw.com
Correspondent Name: THE WEBB LAW FIRM
Address Line 1: ONE GATEWAY CENTER
Address Line 2: 420 FT. DUQUESNE BLVD., SUITE 1200
Address Line 4: PITTSBURGH, PENNSYLVANIA 15222

ATTORNEY DOCKET NUMBER: 3135-1710121
<table>
<thead>
<tr>
<th>NAME OF SUBMITTER:</th>
<th>JOHN W. MCILVAINE, REG. NO. 34,219</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIGNATURE:</td>
<td>/John W. McIlvaine/</td>
</tr>
<tr>
<td>DATE SIGNED:</td>
<td>02/08/2018</td>
</tr>
</tbody>
</table>

Total Attachments: 9

source=1710121ASSIGN#page1.tif
source=1710121ASSIGN#page2.tif
source=1710121ASSIGN#page3.tif
source=1710121ASSIGN#page4.tif
source=1710121ASSIGN#page5.tif
source=1710121ASSIGN#page6.tif
source=1710121ASSIGN#page7.tif
source=1710121ASSIGN#page8.tif
source=1710121ASSIGN#page9.tif
**SCHEDULE of Patent Rights to be transferred according to the DEED OF TRANSFER between ANGIODYNAMICS, INC. AND CLINICAL DEVICES B.V. and BEL HOLDING B.V. AND VELDHOEVE HOLDING B.V.**

<table>
<thead>
<tr>
<th>Attorney Docket Number</th>
<th>U.S. Application No.</th>
<th>U.S. Patent or Publication No.</th>
<th>Filing Date/Issue Date</th>
<th>Invention Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-150</td>
<td>14/022,379</td>
<td>2014/0074049</td>
<td>09/10/2013 / N/A</td>
<td>Catheter Connector for Measurement of Physiological Signals</td>
</tr>
<tr>
<td>P-146A</td>
<td>14/211,801</td>
<td>9,445,746</td>
<td>03/14/2014 / 9/20/2016</td>
<td>Systems and Methods for Catheter Tip Placement Using ECG</td>
</tr>
<tr>
<td>P-146B</td>
<td>14/211,879</td>
<td>9,440,047</td>
<td>03/14/2014 / 9/13/2016</td>
<td>System and Methods for Catheter Tip Placement Using ECG</td>
</tr>
<tr>
<td>P-146 A CIP</td>
<td>15/232,251</td>
<td>2015/0346512</td>
<td>08/09/2016 / N/A</td>
<td>System and Methods for Catheter Tip Placement Using ECG</td>
</tr>
<tr>
<td>P-146 A CON</td>
<td>15/235,376</td>
<td>9,877,665</td>
<td>08/12/2016 / 01/30/2018</td>
<td>System and Methods for Catheter Tip Placement Using ECG</td>
</tr>
</tbody>
</table>
DEED OF TRANSFER

between

ANGIODYNAMICS, INC. AND CLINICAL DEVICES B.V.
as "Assignors"

and

BEL HOLDING B.V. AND VELDHOEVE HOLDING B.V.
as "Assignees"
DEED OF TRANSFER

THE UNDERSIGNED:

1. ANGIODYNAMICS, INC., a company organized under foreign law, having its registered office in New York, United States, with address 14 Plaza Drive, Latham, NY 12110, registered with the Secretary of State of the State of Delaware under number 2305416 for the purpose hereof duly represented by its Senior Vice President and General Counsel, Stephen A. Trowbridge (hereinafter: "AngioDynamics" or "Assignor");

2. CLINICAL DEVICES B.V., a private company with limited liability organized under the laws of the Netherlands (beschoten vennootschap met beperkte aansprakelijkheid), having its registered office in Oss, the Netherlands, with address Hoogheuvelstraat 114, 5349 BA Oss, registered with the commercial register of the Dutch Chamber of Commerce with the number 17238250, for the purpose hereof duly represented by its director AngioDynamics, Inc. (hereinafter "Clinical Devices" or "Assignor");

and

3. BEL HOLDING B.V., a private company with limited liability organized under the laws of the Netherlands (beschoten vennootschap met beperkte aansprakelijkheid), having its registered office in Oss, the Netherlands, with address Heikampstraat 2, 5342 ND Oss, registered with the commercial register of the Dutch Chamber of Commerce with the number 16088661, for the purpose hereof duly represented by its director Lambertus Wilhelms Johannes Elberse (hereinafter: "Bel Holding");

4. VELDHOEVE HOLDING B.V., a private company with limited liability organized under the laws of the Netherlands (beschoten vennootschap met beperkte aansprakelijkheid), having its registered office in Liesel (Deurne), the Netherlands, with address Snoertsebaan 24, 5757 PB Liesel, registered with the commercial register of the Dutch Chamber of Commerce with the number 17238193, for the purpose hereof duly represented by its director Franciscus Ludovicus Maria Johannes Veldhuijzen (hereinafter: "Veldhoeve");

(together also the 'Parties' and each separately also a 'Party');
(AngioDynamics and Clinical Devices also referred to together as 'Assignors');
(Bel Holding and Veldhoeve also referred to together as 'Assignees');

WHEREAS:

A. Until August 2013 Assignees jointly held all shares in the issued share capital of the Dutch company Clinical Devices, a company engaged amongst others in the design,
development and commercialisation of vascular catheter tip location technology through a device which was at that time referred to as the 'TILO' – device and is further described in article 1 (the Device).

B. On 15 August 2013 Assignees entered into a SPA on the basis of which their shares in Clinical Devices were sold and transferred to AngioDynamics (the "Transaction").

C. Assignees and AngioDynamics have been involved in arbitration proceedings before the Netherlands Arbitration Institute (NAI) in relation to the Transaction which proceedings were initiated by Assignees as claimants.

D. On 21st August 2017 the NAI rendered a verdict in which AngioDynamics has been ordered to transfer all right, title and interest in the Device within one month after the arbitral award pursuant to which the Parties have agreed to the transfer described in this deed.

E. This deed of transfer serves to lay down the entire agreement regarding the transfer mentioned under D and to provide the formalities required for a valid transfer in so far as necessary.

AGREE AS FOLLOWS:

1. DEFINITIONS

1.1. In this Deed, unless the context requires otherwise the following terms have the following meaning:

Affiliates: as to any Person (a) any Person which directly or indirectly controls, is controlled by, or is under common control with such Person, and (b) any Person who is a director, officer, partner or principal of such Person or any Person which directly or indirectly controls, is controlled by, or is under common control with such Person. For purposes of this definition, "control" of a Person means the power, direct or indirect, to direct or cause the direction of the management and policies of such Person, appoint and dismiss more than half of the management board of such Person, or to exercise more than half of the voting rights with respect to such Person, in each case, whether by ownership of voting stock, by contract or otherwise.

Deed: this deed of transfer, including the Recitals and the Annex.

Device: the device that was in development originally by Clinical Devices under the project name "Tide" - and later on (also)
under the name "TILO" and/or "Firefly" - intended to be used to determine the location of the tip of a catheter in vivo. This definition also encompasses all versions of the device, including all versions which are developed by or on behalf of the Assignors from 15 August 2013, including Firefly or by using any of the IPR's.

**Documentation:** all documentation relating to the functioning, structure and development of the Device that was in the possession of Clinical Devices at the moment of the Transaction as far as this documentation is still available at Clinical Devices and/or AngioDynamics and/or one or more of their Affiliates and/or documentation that has become available to AngioDynamics and/or one of more its Affiliates and/or Clinical Devices and/or one of more its Affiliates through the Transaction as well as all information on paper and/or digital in relation to and that has resulted from the further development of the Device by and/or for AngioDynamics and/or Clinical Devices or one of more of their Affiliates after the Transaction. The definition of Documentation also includes but is not limited to all source codes and all design material and design files.

**Hardware:** all the versions of the Device (Tilo's and/or Firefly's), as well as monitors, screens and all other hardware that relates to the Device that has been provided to and/or is in the possession of AngioDynamics and/or Clinical Devices and/or any of their Affiliates, and/or which AngioDynamics and/or Clinical Devices and/or any of their Affiliates own.

**IPR's:** all registered and unregistered intellectual property rights of any kind or nature including applications, registrations, continuations, divisionals and continuations-in-part, of without limitation all copyrights, trademarks, including the associated goodwill, design rights, database rights and patent rights regarding or relating to the Device.

**Knowhow:** all Documentation, as far as this Documentation was not publicly available on 17 August 2017.

**Person:** any individual, corporation (including but not limited to any not-for-profit corporation), general or limited partnership, limited liability partnership, joint venture, estate, trust, firm, company (including but not limited to any limited liability company or joint stock company), association, organization, entity or governmental authority.
Rights, title and interest:

all registered and unregistered rights, titles and interest of any kind or nature, including but not limited to the rights mentioned in Annex A.

Transfer Date 9 November 2017.

1.2. No provision of this Deed shall be interpreted against a Party solely as a result of the fact that such Party was responsible for the drafting of such a provision.

1.3. The headings used in this Deed are included for reference purposes only and shall not constitute a part of this Deed for any other purpose and shall not affect the interpretation of any of the provisions of this Deed.

1.4. In this Deed, if the context requires so, words importing the singular number only shall include the plural and vice versa.

2. ALL RIGHTS, TITLE AND INTEREST

2.1. Assignors ensure, before the Transfer Date, that they have obtained all Rights, title and interest relating to the Device, including but not limited to IPR's, Hardware and Documentation.

2.2. In case it turns out that Assignors failed to obtain all relevant Rights, title and interest in the Device before the Transfer Date, they shall inform Assignees of this failure immediately as they become aware of this, and immediately take all actions required to make sure that Assignees will receive all Rights, title and interest in the Device as soon as reasonably possible, without prejudice to the other rights of the Assignees.

3. TRANSFER OF ALL RIGHTS, TITLE AND INTEREST, INCLUDING IPR's

3.1. On the basis of their agreements pursuant to the verdict of the NAI of 21 August 2017, Assignors hereby transfer to Assignees, Irrevocably and without encumbrance, free of charge, which transfer Assignees hereby accept, any and all current and future (claims to) Rights, titles and interest worldwide, related to the Device, including but not limited to IPR's relating to the Device.

3.2. A non-exhaustive list of relevant Rights, titles and IPR's is provided in Annex A.

3.3. Upon the first request of Assignees, Assignors undertake to duly cooperate and do everything that is necessary from their and/or their Affiliates side, for no consideration, in accomplishing the transfer of all Rights, titles and interests related to the Device, including but not limited to the transfer of the current and future IPR's and claims to them related to the Device, to Assignees, including but not limited to the signing of additional deeds and/or contracts and/or other document and/or the registration of Rights, titles and/or interest.
4. **DOCUMENTATION, INFORMATION AND HARDWARE**

4.1. Assignors shall provide Assignees with all Documentation ultimately on the Transfer Date.

4.2. This Documentation shall be provided as is (on paper and/or digital), all in formats that are easily accessible for Assignees.

4.3. Assignors will arrange that all Hardware relating to the Device will be transferred ultimately on the Transfer Date to Assignees by enabling Assignees to exercise the actual control over the Hardware from the Transfer Date.

5. **CONFIDENTIALITY**

5.1. Assignors shall keep the Knowhow strictly confidential, and shall ensure that their Affiliates or third parties that have accessed the Knowhow on the basis of a contractual relationship with AngioDynamics and/or Clinical Devices and/or their Affiliates, remain or will be bound to the same confidentiality obligation.

6. **WARRANTY / MORAL RIGHTS**

6.1. Assignors warrant and guarantee that they are the owners of all the Rights, titles and interest, including but not limited to the IPR’s, relating to the Device, which Rights, titles and interests, including but not limited to the IPR’s, are free from any right of use vested in favour of AngioDynamics and/or one of more its Affiliates. Assignors hereby irrevocably and unconditionally declare that it did not grant any license to any other person/party with regard to the Device prior to this transfer.

6.2. Assignors waive all moral rights which are susceptible of renunciation under applicable copyright laws and waive the right to invoke such provisions.

6.3. Assignors warrant and guarantee that this Deed is validly entered into on behalf of Assignors and that Assignors are entitled to enter into the transfer as described in this Deed.

6.4. Parties explicitly agree that after 21 September 2017 AngioDynamics and/or Clinical Devices and/or any of its Affiliates cannot argue that Rel Holding and/or Veldhoewe Holding infringe any of the Rights, title and/or interest of AngioDynamics and/or Clinical Devices and/or one of more of their Affiliates or any third parties regarding the Device, if they use, exploit or sell the Device or if they use, exploit or sell any right, title and/or interest in the Device.

7. **MISCELLANEOUS**

7.1. The Parties waive the right to annul, rescind or dissolve ('ontbinden') or cancel this Deed, in whole or in part, or to institute a claim at law for the annulment, rescission, dissolution or cancellation of this Deed.

7.2. Each of the Parties involved in this Deed will bear its own costs.

7.3. In the event that any of the provisions contained herein would appear to be void or voidable, the remaining provisions shall remain effective. The Parties undertake to,
at that time, replace the relevant provision with a new provision that is not void or voidable and which provision as closely as possible corresponds with the void or voidable provision, whereby the original intention of the Parties when concluding the Deed is to be taken into consideration as much as possible.

7.4. Amendments to this Deed are only possible and effective to the extent that all Parties have agreed thereto in writing.

8. RESOLUTION OF DISPUTES AND APPLICABLE LAW

8.1. This Deed and any additions to it are solely governed by and construed in accordance with Dutch law.

8.2. Any and all disputes arising between the Parties in relation to this Deed or any further deeds, contracts or agreements that may ensue from it, will be finally settled by arbitration in accordance with the rules of the Netherlands Arbitration Institute (in Dutch: Nederlands Arbitrage Institut). The arbitral tribunal will be composed of three arbitrators appointed in accordance with those rules. The place of the arbitration will be Amsterdam, the Netherlands. The language of the arbitration will be English. The arbitrators will decide according to the rules of law.

THUS AGREED AND SIGNED in quadruplicate.

ANGIODYNAMICS, INC.
By: Stephen A. Trowbridge
Title: Senior Vice President and General Counsel
Place: Latham, New York, USA
Date: 9 November 2017

CLINICAL DEVICES B.V.
By: AngloDynamics, Inc.
By: Stephen A. Trowbridge
Title: Senior Vice President and General Counsel
Date: 9 November 2017

VELDHOEVE HOLDING B.V.
By: L.W.J. Elbersen
Title: director
Place: US
Date: 15-11-2017

REEL: 044865 FRAME: 0549
ANNEX A Rights, title and interest, including but not limited to IPR's

- The EU trade mark 'Tilo' with filing number 011820594
- US patent 'Method for locating a catheter using intracardial ECG/patent for systems and methods for catheter tip placement using ECG, including the entire patent family: the patents with application number 14/211,879, US201615235376 20160812, US201615232251 20160809 and/or US201414211879 20140314;
- Dutch Patent application 'Catheter connector’ with application number NL20122009448 20120911;
- All intellectual property rights regarding Tilo Review System (TRS)